Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Acid Reducing Agents on Palbociclib Bioavailability
NCT02097329Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of palbociclib in breast cancer (2 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 6 days and Maximum Observed Plasma Concentration at 6 days. Started Apr 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02097329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097329.